Chugai launched a new Partnering US Office in South San Francisco, operating from January 2026 under Chugai Pharma USA to enhance collaborations with US academia and startups.13
At the 2026 J.P. Morgan Healthcare Conference (JPM26), Chugai leaders sought greater name recognition in the US biopharma industry while pursuing external partnerships for new technologies like gene therapies and ADCs.2
The company aims for top global healthcare innovator status by 2030 through open innovation, complementing its in-house R&D with deals like Rani Therapeutics for oral antibodies and Araris Biotech for ADC linkers.124
Chugai's innovations include inventing Roche's Hemlibra, Lilly's orforglipron (FDA decision pending), and early protein degradation via 'recycling antibodies' in Enspryng.25
Chugai Venture Fund in Boston invests in US and European early-stage biotechs, recently backing Dualitas Therapeutics.2
Sources:
1. https://www.pharmanow.live/latest-news/chugai-us-office
2. https://www.fiercebiotech.com/biotech/jpm26-chugai-chases-new-science-and-name-recognition-us-biopharma-industry
3. https://pj.jiho.jp/article/254390
4. https://www.marketscreener.com/news/chugai-announces-2025-full-year-results-and-forecasts-for-2026-ce7e5bdcdd81fe22
5. https://www.chugai-pharm.co.jp/english/news/detail/20260129170004_1224.html